26 Oct 2021
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodiumeukaryotic translation elongation factor 2 inhibitor M5717
A first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.